Volume 88 Issue 45 | p. 23 | Concentrates
Issue Date: November 1, 2010

GSK Collaborates With Amicus On A Rare Disease

Pharmaceuticals: The partners will develop a small-molecule treatment for Fabry disease
Department: Business
Keywords: rare diseases, enzymes

GlaxoSmithKline and Amicus Therapeutics have agreed to develop and commercialize Amicus' investigative treatment for Fabry disease, migalastat, which is currently in Phase III clinical trials.

Under the terms of the agreement, GSK will receive an exclusive worldwide license to develop, manufacture, and commercialize migalastat. The two companies will also launch new clinical studies on coadministration of migalastat with enzyme replacement therapy for treatment of the disease.

Fabry disease is a rare . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society